Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Medical Research
Published in: European Journal of Medical Research 1/2023

Open Access 01-12-2023 | Pulmonary Hypertension | Research

FVC/DLCO identifies pulmonary hypertension and predicts 5-year all-cause mortality in patients with COPD

Authors: Yuer Li, Rui Zhang, Hu Shan, Wenhua Shi, Xiaoli Feng, Haijuan Chen, Xia Yang, Yali Li, Jie Zhang, Ming Zhang

Published in: European Journal of Medical Research | Issue 1/2023

Login to get access

Abstract

Background

Pulmonary hypertension (PH) is a common complication of chronic obstructive pulmonary disease (COPD). However, it is unknown whether the ratio of forced vital capacity (FVC) to diffusing lung capacity for carbon monoxide (DLCO) can identify PH in the patients with COPD and predict its prognosis.

Methods

The study population I included 937 COPD patients who were admitted to inpatient treatments from 2010 to 2017, and finally 750 patients were available to follow-up the 5-year all-cause mortality (study population II). Clinical characteristics of the study population were recorded.

Results

COPD patients with PH had a higher FVC/DLCO value compared with the patients without PH. The threshold for FVC/DLCO to identify PH in COPD patients was 0.44 l/mmol/min/kPa. Multivariate logistic regression analysis showed that FVC/DLCO was a significant predictor for PH in the patients with COPD. The study population II showed that the 5-year all-cause mortality of COPD patients was significantly higher in combined with PH group than without PH group. Compared with the survivor group, FVC/DLCO value was significantly increased in non-survivor group. The threshold for FVC/DLCO to predict 5-year all-cause mortality was 0.41 l/mmol/min/kPa. Kaplan–Meier survival curves showed that 5-year cumulative survival rate for COPD patients were significantly decreased when the value of FVC/DLCO was ≥ 0.41 l/mmol/min/kPa. Multivariate cox regression analysis showed that FVC/DLCO was an independent prognostic factor for 5-year all-cause mortality in COPD patients.

Conclusion

FVC/DLCO could identify PH in the patients with COPD and was an independent predictor for 5-year all-cause mortality of COPD.
Appendix
Available only for authorised users
Literature
1.
Mortality GBD, Causes of Death C. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385:117–71.CrossRef
2.
Christenson SA, Smith BM, Bafadhel M, Putcha N. Chronic obstructive pulmonary disease. Lancet. 2022;399:2227–42.CrossRefPubMed
3.
Decramer M, Janssens W. Chronic obstructive pulmonary disease and comorbidities. Lancet Respir Med. 2013;1:73–83.CrossRefPubMed
4.
Carlin BW. COPD and associated comorbidities: a review of current diagnosis and treatment. Postgrad Med. 2012;124:225–40.CrossRefPubMed
5.
Blanco I, Tura-Ceide O, Peinado VI, Barbera JA. Updated perspectives on pulmonary hypertension in COPD. Int J Chron Obstruct Pulmon Dis. 2020;15:1315–24.CrossRefPubMedPubMedCentral
6.
Kessler R, Faller M, Weitzenblum E, Chaouat A, Aykut A, Ducolone A, Ehrhart M, Oswald-Mammosser M. “Natural history” of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease. Am J Respir Crit Care Med. 2001;164:219–24.CrossRefPubMed
7.
Thabut G, Dauriat G, Stern JB, Logeart D, Levy A, Marrash-Chahla R, Mal H. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest. 2005;127:1531–6.CrossRefPubMed
8.
Scharf SM, Iqbal M, Keller C, Criner G, Lee S, Fessler HE, National Emphysema Treatment Trial G. Hemodynamic characterization of patients with severe emphysema. Am J Respir Crit Care Med. 2002;166:314–22.CrossRefPubMed
9.
Torres-Castro R, Gimeno-Santos E, Vilaro J, Roque-Figuls M, Moises J, Vasconcello-Castillo L, Orizaga T, Barbera JA, Blanco I. Effect of pulmonary hypertension on exercise tolerance in patients with COPD: a prognostic systematic review and meta-analysis. Eur Respir Rev. 2021;30:200321.CrossRefPubMedPubMedCentral
10.
Kessler R, Faller M, Fourgaut G, Mennecier B, Weitzenblum E. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;159:158–64.CrossRefPubMed
11.
Cuttica MJ, Kalhan R, Shlobin OA, Ahmad S, Gladwin M, Machado RF, Barnett SD, Nathan SD. Categorization and impact of pulmonary hypertension in patients with advanced COPD. Respir Med. 2010;104:1877–82.CrossRefPubMed
12.
Andersen KH, Iversen M, Kjaergaard J, Mortensen J, Nielsen-Kudsk JE, Bendstrup E, Videbaek R, Carlsen J. Prevalence, predictors, and survival in pulmonary hypertension related to end-stage chronic obstructive pulmonary disease. J Heart Lung Transplant. 2012;31:373–80.CrossRefPubMed
13.
Gredic M, Blanco I, Kovacs G, Helyes Z, Ferdinandy P, Olschewski H, Barbera JA, Weissmann N. Pulmonary hypertension in chronic obstructive pulmonary disease. Br J Pharmacol. 2021;178:132–51.CrossRefPubMed
14.
Vizza CD, Hoeper MM, Huscher D, Pittrow D, Benjamin N, Olsson KM, Ghofrani HA, Held M, Klose H, Lange T, et al. Pulmonary hypertension in patients with COPD: results from the comparative, prospective registry of newly initiated therapies for pulmonary hypertension (COMPERA). Chest. 2021;160:678–89.CrossRefPubMed
15.
16.
Rosenkranz S, Gibbs JS, Wachter R, De Marco T, Vonk-Noordegraaf A, Vachiery JL. Left ventricular heart failure and pulmonary hypertension. Eur Heart J. 2016;37:942–54.CrossRefPubMed
17.
Papamatheakis DG, Poch DS, Fernandes TM, Kerr KM, Kim NH, Fedullo PF. Chronic thromboembolic pulmonary hypertension: JACC focus seminar. J Am Coll Cardiol. 2020;76:2155–69.CrossRefPubMed
18.
Lurie A, Roche N. Obstructive sleep apnea in patients with chronic obstructive pulmonary disease: facts and perspectives. COPD. 2021;18:700–12.CrossRefPubMed
19.
Chaouat A, Bugnet AS, Kadaoui N, Schott R, Enache I, Ducolone A, Ehrhart M, Kessler R, Weitzenblum E. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;172:189–94.CrossRefPubMed
20.
21.
Tsujimoto Y, Kumasawa J, Shimizu S, Nakano Y, Kataoka Y, Tsujimoto H, Kono M, Okabayashi S, Imura H, Mizuta T. Doppler trans-thoracic echocardiography for detection of pulmonary hypertension in adults. Cochrane Database Syst Rev. 2022;5:CD012809.PubMed
22.
Zhang RF, Zhou L, Ma GF, Shao FC, Wu XH, Ying KJ. Diagnostic value of transthoracic Doppler echocardiography in pulmonary hypertension: a meta-analysis. Am J Hypertens. 2010;23:1261–4.CrossRefPubMed
23.
Charalampopoulos A, Raphael C, Gin-Sing W, Gibbs JS. Diagnosing and managing pulmonary hypertension. Practitioner. 2012;256(21–25):22–3.
24.
Donato L, Giovanna Elisiana C, Giuseppe G, Pietro S, Michele C, Brunetti ND, Valentina V, Matteo DB, Maria Pia FB. Utility of FVC/DLCO ratio to stratify the risk of mortality in unselected subjects with pulmonary hypertension. Intern Emerg Med. 2017;12:319–26.CrossRefPubMed
25.
Steen VD, Graham G, Conte C, Owens G, Medsger TA Jr. Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum. 1992;35:765–70.CrossRefPubMed
26.
Mirza S, Clay RD, Koslow MA, Scanlon PD. COPD Guidelines: a review of the 2018 GOLD report. Mayo Clin Proc. 2018;93:1488–502.CrossRefPubMed
27.
Tarrass F, Benjelloun M, Medkouri G, Hachim K, Benghanem MG, Ramdani B. Doppler echocardiograph evaluation of pulmonary hypertension in patients undergoing hemodialysis. Hemodial Int. 2006;10:356–9.CrossRefPubMed
28.
29.
Weitzenblum E, Hirth C, Ducolone A, Mirhom R, Rasaholinjanahary J, Ehrhart M. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax. 1981;36:752–8.CrossRefPubMedPubMedCentral
30.
Hurdman J, Condliffe R, Elliot CA, Swift A, Rajaram S, Davies C, Hill C, Hamilton N, Armstrong IJ, Billings C, et al. Pulmonary hypertension in COPD: results from the ASPIRE registry. Eur Respir J. 2013;41:1292–301.CrossRefPubMed
31.
Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A, Weitzenblum E, Cordier JF, Chabot F, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173:1023–30.CrossRefPubMed
32.
Brown LM, Chen H, Halpern S, Taichman D, McGoon MD, Farber HW, Frost AE, Liou TG, Turner M, Feldkircher K, et al. Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry. Chest. 2011;140:19–26.CrossRefPubMedPubMedCentral
33.
Alter P, Orszag J, Kellerer C, Kahnert K, Speicher T, Watz H, Bals R, Welte T, Vogelmeier CF, Jorres RA. Prediction of air trapping or pulmonary hyperinflation by forced spirometry in COPD patients: results from COSYCONET. ERJ Open Res 2020; 6.
34.
Rose L, Prins KW, Archer SL, Pritzker M, Weir EK, Misialek JR, Thenappan T. Survival in pulmonary hypertension due to chronic lung disease: influence of low diffusion capacity of the lungs for carbon monoxide. J Heart Lung Transplant. 2019;38:145–55.CrossRefPubMed
35.
Choi J, Sim JK, Oh JY, Lee YS, Hur GY, Lee SY, Shim JJ, Rhee CK, Min KH. Prognostic marker for severe acute exacerbation of chronic obstructive pulmonary disease: analysis of diffusing capacity of the lung for carbon monoxide (D(LCO)) and forced expiratory volume in one second (FEV(1)). BMC Pulm Med. 2021;21:152.CrossRefPubMedPubMedCentral
36.
Takemura M, Mitsui K, Itotani R, Ishitoko M, Suzuki S, Matsumoto M, Aihara K, Oguma T, Ueda T, Kagioka H, Fukui M. Relationships between repeated instruction on inhalation therapy, medication adherence, and health status in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2011;6:97–104.CrossRefPubMedPubMedCentral
37.
de Torres JP, O’Donnell DE, Marin JM, Cabrera C, Casanova C, Marin M, Ezponda A, Cosio BG, Martinez C, Solanes I, et al. Clinical and prognostic impact of low diffusing capacity for carbon monoxide values in patients with global initiative for obstructive lung disease I COPD. Chest. 2021;160:872–8.CrossRefPubMed
Metadata
Title
FVC/DLCO identifies pulmonary hypertension and predicts 5-year all-cause mortality in patients with COPD
Authors
Yuer Li
Rui Zhang
Hu Shan
Wenhua Shi
Xiaoli Feng
Haijuan Chen
Xia Yang
Yali Li
Jie Zhang
Ming Zhang
Publication date
01-12-2023
Publisher
BioMed Central
Published in
European Journal of Medical Research / Issue 1/2023
Electronic ISSN: 2047-783X
DOI
https://doi.org/10.1186/s40001-023-01130-6

Other articles of this Issue 1/2023

European Journal of Medical Research 1/2023 Go to the issue

Review

Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases

Research

Study on anxiety and depression in elderly patients with malignant liver tumor undergoing hepatectomy

Research

Metastasis of breast cancer to bones alters the tumor immune microenvironment

Review

Facial nerve in skullbase tumors: imaging and clinical relevance

Research

Prolyl 4-hydroxylase subunit beta (P4HB) could serve as a prognostic and radiosensitivity biomarker for prostate cancer patients

Research

Peripheral arterial tonometry versus polysomnography in suspected obstructive sleep apnoea